Parkinson's drug discovery is constrained by species differences, patient variability, and imperfect laboratory models. Learn how human iPSC-derived neurons and brain organoids can improve disease modeling and preclinical decisions.
Parkinson's disease research faces a familiar but costly problem: a compound can show promise in a laboratory model yet fail to produce meaningful benefits...